Bristol-Myers Squibb BMY EPS (Diluted)
EPS (Diluted) at other companies
Other financials
Where this comes from
Reported directly by Bristol-Myers Squibb in its filing.
Tagged under the XBRL concept us-gaap:EarningsPerShareDiluted.
The official record: Bristol-Myers Squibb’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →
Ask your AI about Bristol-Myers Squibb's eps (diluted).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Bristol-Myers Squibb's EPS (diluted)?
- Bristol-Myers Squibb (BMY) reported EPS (diluted) of $1.31 in Q1 2026.
- How has Bristol-Myers Squibb's EPS (diluted) changed year-over-year?
- Bristol-Myers Squibb's EPS (diluted) increased by 9.2% year-over-year, from $1.20 to $1.31.
- What is the long-term trend for Bristol-Myers Squibb's EPS (diluted)?
- Over 4 years (2021 to 2025), Bristol-Myers Squibb's EPS (diluted) has grown at a 2.5% compound annual growth rate (CAGR), from $3.12 to $3.45.
- What does EPS (diluted) mean?
- Net income divided by the weighted-average number of shares outstanding plus all potentially dilutive securities (stock options, convertibles, warrants). The most conservative EPS measure.